INS and hepatocellular carcinoma: SGLT2 inhibitors, primarily used for managing type 2 diabetes (T2DM), improve glycemic control and reduce insulin resistance, both of which are implicated in the development of HCC, as shown in the mechanisms summarized in Figure 1.